Description

Pharmacokinetic considerations for phytocannabinoids in epilepsy management include bioavailability, metabolism, and drug-drug interactions. CYP450 interactions with antiepileptic drugs require clinical monitoring.

Figure 20

Diagram

Source Paper

Receptors and Channels Possibly Mediating the Effects of Phytocannabinoids on Seizures and Epilepsy.

Pharmaceuticals (Basel, Switzerland) (2020)

PMID: 32751761

DOI: 10.3390/ph13080174

Cite This Figure

![Figure 20: Pharmacokinetic considerations for phytocannabinoids in epilepsy management include bioavailability, metabolism, and drug-drug interactions. CYP450 interactions with antiepileptic drugs require clinical monitoring.]()

> Source: Lara Senn et al. "Receptors and Channels Possibly Mediating the Effects of Phytocannabinoids on Se." *Pharmaceuticals (Basel, Switzerland)*, 2020. PMID: [32751761](https://pubmed.ncbi.nlm.nih.gov/32751761/)

<figure>
  <img src="" alt="Pharmacokinetic considerations for phytocannabinoids in epilepsy management include bioavailability, metabolism, and drug-drug interactions. CYP450 interactions with antiepileptic drugs require clinical monitoring." />
  <figcaption>Figure 20. Pharmacokinetic considerations for phytocannabinoids in epilepsy management include bioavailability, metabolism, and drug-drug interactions. CYP450 interactions with antiepileptic drugs require clinical monitoring.<br>  Source: Lara Senn et al. "Receptors and Channels Possibly Mediating the Effects of Phytocannabinoids on Se." <em>Pharmaceuticals (Basel, Switzerland)</em>, 2020. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/32751761/">32751761</a></figcaption>
</figure>

Preuves associées

CBD pour Insomnie

Note A · 103 études